LUNG Pulmonx Corporation

Medical Device Company
19.22
+0.7  (+4%)
Previous Close 18.52
Open 18.79
52 Week Low 15.06
52 Week High 45.81
Market Cap $713,380,975
Shares 37,116,596
Float 29,472,068
Enterprise Value $543,839,357
Volume 363,701
Av. Daily Volume 471,583
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Citigroup Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/17/2022

Latest News

  1. REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022.

    Recent Highlights

    • Recorded worldwide revenue of $10.8 million in the first quarter of 2022, a 17% increase over the same period last year and an increase of 20% on a constant currency basis
    • Realized gross margin of 75% in the first quarter of 2022 as compared to 72% in the same period last year
    • Added 16 new U.S. treatment centers for Zephyr Valves in the first quarter 2022, increasing total U.S. treatment centers to 230

    "We are encouraged by our first quarter performance as we benefited…

    View Full Article
  2. REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May 3, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

    Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 2575271. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/

    View Full Article
View All Pulmonx Corporation News